The development of GIPR–GLP-1R co-agonists have been a major advancement in the treatment of obesity and diabetes9, but the mechanisms through which GIP affects systemic energy metabolism remain largely unknown. Accumulating evidence indicates that long-acting GIPR agonists act in the brain to decrease body weight through inhibition of food intake3,6,7,8. Chemogenetic activation of hypothalamic and …
